# A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome

> **NCT05098509** · PHASE2,PHASE3 · TERMINATED · sponsor: **Radius Pharmaceuticals, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** RAD011
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05098509
- **Lead sponsor:** Radius Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-13
- **Primary completion:** 2022-10-06
- **Final completion:** 2022-10-31
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Due to a change in corporate priorities, this study was voluntarily terminated by the Sponsor for reasons other than safety
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098509, "A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05098509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*